Lilly’s positioning paper to improve the EU Clinical trial environment
Clinical trials in European have been declining with 10% in the last decade. To increase competitiveness of clinical trials in Europe, Lilly recommends to improving CT-R implementation, by review efficiency, resolving minor CTA issues through informal dialogue, and addressing IVDR complexities.
Policy Positions
Toggle view
Loading...